Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting

Company secures four oral presentations, including three that will
highlight new data demonstrating activity of rezafungin against Candida
auris and azole-resistant Aspergillus

SAN DIEGO–(BUSINESS WIRE)–Apr. 4, 2018–
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical studies of its lead antifungal
rezafungin will be presented at the 28th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID) to be held in Madrid,
Spain, April 21-24, 2018.

“At this year’s ECCMID meeting Ci…

READ FULL TEXT

Leave a Reply

Your email address will not be published.